Carbidopa/oxitriptan

Carbidopa/oxitriptan (developmental code name EVX-101), or carbidopa/5-hydroxytryptophan (carbidopa/5-HTP), is a combination of 5-hydroxytryptophan (oxitriptan), a serotonin precursor, and carbidopa, a peripherally selective aromatic L-amino acid decarboxylase inhibitor, which is under development as an antidepressant for the treatment of depressive disorders.[1] As of June 2020, it is in phase 1 clinical trials for this indication.[1]

Carbidopa / oxitriptan
Carbidopa (top) and oxitriptan (bottom)
Combination of
CarbidopaAromatic L-amino acid decarboxylase inhibitor
OxitriptanSerotonin precursor
Clinical data
Other namesCarbidopa/5-hydroxytryptophan; Carbidopa/L-5-hydroxytryptophan; Carbidopa/5-HTP; Carbidopa/L-5-HTP; EVX-101
Routes of
administration		Oral administration

References
  1. "Carbidopa/oxytriptan - Evecxia". AdisInsight. Springer Nature Switzerland AG.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.